EIKN (NASDAQ:EIKN) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of EIKN (NASDAQ:EIKN) have been given an average recommendation of “Moderate Buy” by the seven analysts that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $25.20.

Several equities research analysts have commented on the stock. Wedbush dropped their price objective on shares of EIKN from $7.00 to $5.00 and set an “underperform” rating on the stock in a report on Tuesday. Morgan Stanley started coverage on shares of EIKN in a report on Monday, March 2nd. They issued an “overweight” rating and a $32.00 price target on the stock. Cantor Fitzgerald started coverage on shares of EIKN in a report on Monday, March 2nd. They issued an “overweight” rating on the stock. Zacks Research raised shares of EIKN to a “hold” rating in a report on Friday, February 27th. Finally, JPMorgan Chase & Co. started coverage on shares of EIKN in a research report on Monday, March 2nd. They issued an “overweight” rating and a $29.00 price objective on the stock.

EIKN Trading Up 0.5%

NASDAQ EIKN opened at $13.25 on Friday. EIKN has a 52 week low of $7.90 and a 52 week high of $17.40. The firm’s 50-day simple moving average is $10.98.

EIKN (NASDAQ:EIKN) last released its quarterly earnings data on Monday, March 30th. The company reported ($26.23) EPS for the quarter.

EIKN Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.